Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Description and Educational Objectives

In this activity, an expert in pulmonology discusses the latest clinical data informing evidence-based treatment of moderate-to-severe, persistent asthma.

Upon completion of this activity, participants should be better able to:

• Evaluate the most recent efficacy and safety data for biologics for treatment of moderate-to-severe, persistent asthma
• Identify prognostic and predictive biomarkers that may improve therapeutic selection for patients with moderate-to-severe, persistent asthma
• Outline evidence-based treatment selection strategies that have been demonstrated to improve care of patients with persistent, uncontrolled asthma

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, respirologists, allergists, immunologists, and other clinicians involved in the treatment of asthma.

Faculty Disclosure Statement / Conflict of Interest Policy

Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Faculty

Mario Castro, MD, MPH
Chief, Pulmonary, Critical Care, and Sleep Medicine
University of Kansas School of Medicine
Kansas City, Kansas, USA

Mario Castro, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Genentech; Novartis; Sanofi-Aventis; and Teva.
Grant/Research Support from American Lung Association; AstraZeneca; Chiesi; GlaxoSmithKlein; National Institutes of Health; Novartis; Patient-Centered Outcomes Research Institute; and Sanofi-Aventis.
Speakers Bureau participant with AstraZeneca; Genentech; GlaxoSmithKlein; Regeneron; Sanofi-Aventis; and Teva.
Honoraria from AstraZeneca; Genentech; GlaxoSmithKlein; Regeneron; Sanofi-Aventis; and Teva.

Answers in CME Medical Director

Serena Welch, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and Answers in CME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

This CME activity is jointly provided by Oakstone Publishing and Answers in CME.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 80% is needed.

Media: Enduring Material
Release and Expiration Dates: September 30, 2020 - September 29, 2021
Time to Complete: 30 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Answers in CME or any of its supporters.

© 2018-2020, Answers in CME